Day Two

Thursday, January 20, 2022

8:00 am Chair’s Opening Remarks

A Deep Dive into DNA Damage Repair for GBM

8:10 am Targeting DNA Repair in Glioblastoma: New Era of Brain Penetrant Agents


  • Aberrant DNA repair in malignant gliomas
  • Functional interplay between cancer cell metabolism and DNA repair
  • Brain penetrant DNA repair inhibitor efficacy in malignant gliomas

8:40 am Inovio’s DNA Medicine for the Treatment of Glioblastoma


  • Using novel DNA-encoded medicines to treat human cancers such as GBM
  • Generating robust, specific anti-tumor T cells against GBM antigens
  • Combining DNA medicine with immune checkpoint inhibitors to build
    clinical responses

9:10 am Targeting the DNA Damage Response in Glioma: Emerging New Concepts and Novel Directions

  • Ranjit Bindra Professor, Therapeutic Radiology, Yale University School of Medicine


  • Overview of the DNA damage response (DDR) and how it can be targeted therapeutically for GBM
  • Review on promising new DDR inhibitors and DNA damaging agents, which are either in development or in the clinic for GBM
  • Discuss emerging DDR targets, key hurdles, and future directions in the GBM space

9:40 am Morning Break & Networking

Financing BioPharma for Rapid GBM Drug Development

10:40 am Panel: It’s All in the Money – Funding Challenges & Opportunities in the GBM Space

  • Kirk Tanner Chief Scientific Officer, National Brain Tumor Society
  • Mike Goguen Founder & Managing Partner, Two Bear Capital
  • Becky Bish Head of Discovery & Preclinical Research, The Mark Foundation
  • Klaus Veitinger Venture Partner, OrbiMed Advisors
  • Neil White Investment Manager Health, Emerson Collective
  • Suzanne Forry Program Director, Preclinical Therapeutics Grants Branch, National Cancer Institute


  • Explore the challenges of funding development
  • How can drug developers inspire and attract companies to invest in their novel preclinical glioblastoma development and pipeline?
  • How can the industry come together to overcome the paucity of funding?

Optimizing Immunotherapies for GBM Drug Development

11:40 am Immunotherapy of Brain Cancer: Past, Present and Future

  • Marnix Bosch Chief Technology Officer, NorthWest Biotherapeutics


  • Challenges of designing & evaluating clinical trials for immunotherapies in the GBM field
  • Strategies to sensitize glioblastoma to immune therapies
  • Exploring immune therapy resistance in glioblastoma

12:10 pm Mechanisms of Immunosuppression

  • Michael Lim Professor & Chair Department of Neuro Surgery, Stanford University School of Medicine


  • Understand current landscape of immunotherapy for brain tumors
  • Understand the current obstacles for developing effective immunotherapies for brain tumors

12:40 pm Lunch & Networking

1:40 pm Leveraging the Lysosome to Treat Glioblastoma

  • Jim Beach Chief Operating Officer, Bexion Pharmaceuticals


  • BXQ-350 – a unique, first in class, lysosomal protein (in lipid nanovesicle) involved in cellular homeostasis
  • Phase 1 clinical trial findings of extraordinary safety and tolerability with monotherapy effect
  • Planned clinical trials in newly diagnosed GBM – combination therapy
    with radiation and temozolomide

2:10 pm Optimization of an Oncolytic HSV-1 for the Treatment of Glioblastoma


  • Optimization of oHSV backbone 7 Transgenes
  • Development of clinical candidate oncolytic virus

2:40 pm STINGing GBM


  • Characterization of the unique immune biology of the glioblastoma microenvironment
  • Background on the role of the STING activation pathway in glioblastoma
  • Preclinical data of STING agonists and potential lead candidates for  clinical trials

3:10 pm Targeting Clonal Heterogeneity In Treatment-Refractory GBM With Empiric Polytherapy


  • Review the biological profile of treatment-refractory glioblastoma
  • Explore the application of an integrative multi-omics target discovery platform for human GBM which incorporates DNA cellular barcoding, glycocapture profiling of the cell surface proteome, RNA sequencing, single-cell sequencing and genome-wide CRISPR screening of primary and recurrent GBM
  • Review the rationale for combinatorial polytherapy for targeting intratumoral heterogeneity and therapy-driven clonal evolution found in GBM recurrence

3:10 pm Afternoon Break & Refreshments

4:10 pm Novel Hydrogel-Based Localized Treatment For Glioblastoma


  • Discovery of a novel target for Glioblastoma using a machine learning algorithm
  • Development of a tailored hydrogel-based drug delivery system to be used as adjunct to surgery
  • Presentation of preclinical in vitro and in vivo data supporting clinical

4:40 pm Targeting Circadian Clock Proteins in Glioblastoma

  • Steve Kay Professor of Neurology, Keck School of Medicine


  • Clock proteins exhibit aberrant functions in glioblastoma stem cells
  • We are developing a series of small molecule tool compounds that target the activity of clock proteins
  • Preclinical data will be presented assessing the potential for novel

5:10 pm Xenogeneic Corneal Epithelial Cells Derived Vesicles Containing P53 as a Novel GBM Therapy


  • Utilization of extracellular vesicles as delivery vehicle in brain tumors
  • Preclinical results accumulated by ExoProTher

5:40 pm End of Day Two